BioSpace News Archive

Hillrom (NYSE: HRC) today announced it has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies.

Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female pelvic floor disorders, today announced the appointment of Eileen Maus in Q4 2020 as the company’s president and CEO. Under her leadership, Renovia completed

New Global Industry Coalition That Aims to Dramatically Increase Access for All Patients Populations in Clinical Trials and Research Launches

- $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies - Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma - $2 million Phase II Small Business Innovation Research (SBIR) grant awarded to fund development activities and advance preclinical studies of VMT-

SAM Medical Products is pleased to announce the product launch of SAM ThoraSite® , a device to improve accuracy of lateral decompression needle and chest tube placement . The addition of ThoraSite expands the Respiratory Management Product Line, and is the second product to be released in less than a year for SAM Me

The American Cancer Society announced that life sciences industry leader Alice Pomponio has been named managing director of BrightEdge, the ACS philanthropic impact fund that invests in companies to accelerate the Society’s mission to fight cancer.

XORTX Therapeutics Inc. (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a synopsis of 2020 achievements and guidance on key activities for 2021.

As previously reported on December 7, 2020 preliminary results achieved during the feasibility studies indicated a test sensitivity of 80% and a specificity of over 90% for Therma’s CoviSafe™.

Dr. McNulty joins as an experienced biotechnology executive with over 20 years’ experience in drug development having previously held positions at Pfizer, GSK, Syntaxin, ImmBio, Biosceptre and Inflection Biosciences.

The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), exercised their option to enter Phase II of a multi-phase contract to continue physIQ’s development of an AI-based COVID-19 digital biomarker to address the rapid decompensation of high-risk COVID-19 patients.